In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

BACKGROUND: Colorectal cancer (CRC) is one of the most prevalent and deadly tumors worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based cancer immunotherapy, with approximately 15% with high-microsatellite instability, high tumor mutation burden, and intratumoral...

Descripción completa

Detalles Bibliográficos
Autores principales: Ieranò, Caterina, Righelli, Dario, D'Alterio, Crescenzo, Napolitano, Maria, Portella, Luigi, Rea, Giuseppina, Auletta, Federica, Santagata, Sara, Trotta, Anna Maria, Guardascione, Giuseppe, Liotti, Federica, Prevete, Nella, Maiolino, Piera, Luciano, Antonio, Barbieri, Antonio, Di Mauro, Annabella, Roma, Cristin, Esposito Abate, Riziero, Tatangelo, Fabiana, Pacelli, Roberto, Normanno, Nicola, Melillo, Rosa Marina, Scala, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900051/
https://www.ncbi.nlm.nih.gov/pubmed/35246475
http://dx.doi.org/10.1136/jitc-2021-004032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900051/
https://www.ncbi.nlm.nih.gov/pubmed/35246475
http://dx.doi.org/10.1136/jitc-2021-004032

Ejemplares similares